12/23
07:30 am
dyn
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
Low
Report
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
12/22
07:02 am
dyn
Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) [Yahoo! Finance]
Medium
Report
Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) [Yahoo! Finance]
12/20
01:30 am
dyn
Dyne Therapeutics (NASDAQ:DYN) was upgraded by analysts at
Wall Street Ze
Medium
Report
Dyne Therapeutics (NASDAQ:DYN) was upgraded by analysts at
Wall Street Ze
12/15
09:11 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
12/11
07:03 pm
dyn
Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial [Yahoo! Finance]
Low
Report
Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial [Yahoo! Finance]
12/11
04:05 pm
dyn
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Low
Report
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
12/11
08:44 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target raised by analysts at Stifel Nicolaus from $36.00 to $39.00. They now have a "buy" rating on the stock.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target raised by analysts at Stifel Nicolaus from $36.00 to $39.00. They now have a "buy" rating on the stock.
12/10
11:43 am
dyn
Dyne Therapeutics: Why The $350M Public Offering Was Critical [Seeking Alpha]
Low
Report
Dyne Therapeutics: Why The $350M Public Offering Was Critical [Seeking Alpha]
12/10
07:20 am
dyn
Dyne Therapeutics (NASDAQ:DYN) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.
12/9
09:42 pm
dyn
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
Medium
Report
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
12/9
01:03 pm
dyn
Dyne Therapeutics (NASDAQ:DYN) was given a new $23.00 price target on by analysts at Tudor Pickering.
Medium
Report
Dyne Therapeutics (NASDAQ:DYN) was given a new $23.00 price target on by analysts at Tudor Pickering.
12/9
08:47 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $38.00 price target on the stock.
High
Report
Dyne Therapeutics (NASDAQ:DYN) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $38.00 price target on the stock.
12/9
08:44 am
dyn
Dyne Therapeutics (NASDAQ:DYN) was given a new $23.00 price target on by analysts at Sanford C. Bernstein.
High
Report
Dyne Therapeutics (NASDAQ:DYN) was given a new $23.00 price target on by analysts at Sanford C. Bernstein.
12/8
04:02 pm
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
High
Report
Dyne Therapeutics (NASDAQ:DYN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/8
04:02 pm
dyn
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
High
Report
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
12/8
01:01 pm
dyn
Dyne Therapeutics (NASDAQ:DYN) was given a new $30.00 price target on by analysts at Robert W. Baird.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) was given a new $30.00 price target on by analysts at Robert W. Baird.
12/8
12:13 pm
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
Dyne Therapeutics (NASDAQ:DYN) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/8
11:02 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Medium
Report
Dyne Therapeutics (NASDAQ:DYN) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/8
09:56 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target raised by analysts at HC Wainwright from $46.00 to $60.00. They now have a "buy" rating on the stock.
Medium
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target raised by analysts at HC Wainwright from $46.00 to $60.00. They now have a "buy" rating on the stock.
12/8
06:30 am
dyn
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Low
Report
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
12/7
11:00 am
dyn
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
High
Report
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
11/30
12:37 am
dyn
Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release [Yahoo! Finance]
Medium
Report
Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release [Yahoo! Finance]
11/25
07:19 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.
11/14
10:56 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.
11/12
11:30 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $13.00 to $11.00. They now have a "market perform" rating on the stock.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $13.00 to $11.00. They now have a "market perform" rating on the stock.